- Home
- MRAM vs BMEA Comparison
MRAM vs BMEA Comparison
Compare MRAM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- BMEA
- Stock Information
- Founded
- MRAM 2008
- BMEA 2017
- Country
- MRAM United States
- BMEA United States
- Employees
- MRAM N/A
- BMEA N/A
- Industry
- MRAM Semiconductors
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- BMEA Health Care
- Exchange
- MRAM Nasdaq
- BMEA Nasdaq
- Market Cap
- MRAM 114.4M
- BMEA 65.8M
- IPO Year
- MRAM 2016
- BMEA 2021
- Fundamental
- Price
- MRAM $6.75
- BMEA $1.93
- Analyst Decision
- MRAM Strong Buy
- BMEA Strong Buy
- Analyst Count
- MRAM 1
- BMEA 10
- Target Price
- MRAM $8.00
- BMEA $22.30
- AVG Volume (30 Days)
- MRAM 216.5K
- BMEA 2.2M
- Earning Date
- MRAM 07-30-2025
- BMEA 07-30-2025
- Dividend Yield
- MRAM N/A
- BMEA N/A
- EPS Growth
- MRAM N/A
- BMEA N/A
- EPS
- MRAM N/A
- BMEA N/A
- Revenue
- MRAM $49,110,000.00
- BMEA N/A
- Revenue This Year
- MRAM $9.48
- BMEA N/A
- Revenue Next Year
- MRAM $12.85
- BMEA N/A
- P/E Ratio
- MRAM N/A
- BMEA N/A
- Revenue Growth
- MRAM N/A
- BMEA N/A
- 52 Week Low
- MRAM $4.34
- BMEA $1.29
- 52 Week High
- MRAM $7.02
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- MRAM 62.00
- BMEA 50.04
- Support Level
- MRAM $6.70
- BMEA $1.58
- Resistance Level
- MRAM $6.94
- BMEA $2.03
- Average True Range (ATR)
- MRAM 0.24
- BMEA 0.15
- MACD
- MRAM 0.03
- BMEA -0.00
- Stochastic Oscillator
- MRAM 74.30
- BMEA 80.00
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.